Skip to content

Study · Non-randomized trial · 1995

4 results

Short term effect of intranasal administration of hexarelin--a synthetic growth hormone-releasing peptide. Preliminary communication.

Frenkel J, Silbergeld A, Deghenghi R, Laron Z

Journal of pediatric endocrinology & metabolism : JPEM1 Jan 1995Cited by 5 (Europe PMC)

PMID7584696 (opens in a new tab)DOI10.1515/jpem.1995.8.1.43 (opens in a new tab)PepBankPUB-07584696
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with short stature and normal GH secretion, 7 days of intranasal hexarelin raised serum IGF-1 significantly.

    In plain wordsIn children with short stature, a week of hexarelin nasal doses raised blood levels of IGF-1.

    Peptide
    Hexarelin
    Outcome
    IncreaseSerum IGF-1
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intranasal · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Twice or three times daily intranasal administration of the hexapeptide hexarelin for 7 days to children with short stature and normal growth hormone (GH) secretion evoked a significant rise in serum levels of insulin-like growth factor-1 (IGF-1) and alkaline phosphatase.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with short stature and normal GH secretion, 7 days of intranasal hexarelin raised serum alkaline phosphatase significantly.

    In plain wordsIn children with short stature, a week of hexarelin nasal doses raised blood alkaline phosphatase.

    Peptide
    Hexarelin
    Outcome
    IncreaseSerum alkaline phosphatase
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Twice or three times daily intranasal administration of the hexapeptide hexarelin for 7 days to children with short stature and normal growth hormone (GH) secretion evoked a significant rise in serum levels of insulin-like growth factor-1 (IGF-1) and alkaline phosphatase.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with short stature, intranasal hexarelin raised TSH significantly but within normal limits.

    In plain wordsIn children with short stature, hexarelin nasal doses raised TSH, but the level stayed within the normal range.

    Peptide
    Hexarelin
    Outcome
    IncreaseSerum TSH
    Study

    n: not reported in source

    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · intranasal · 7 daysAs given in this study (human).

    Source sentences

    Summary
    There was also a significant, within normal limits, rise of thyroid stimulating hormone (TSH) without evidence of thyroxine suppression.
    1 context sentence
    Summary · context
    Twice or three times daily intranasal administration of the hexapeptide hexarelin for 7 days to children with short stature and normal growth hormone (GH) secretion evoked a significant rise in serum levels of insulin-like growth factor-1 (IGF-1) and alkaline phosphatase.
  4. 04HumanNon-randomized trialSafety outcome

    In children with short stature, the TSH rise during intranasal hexarelin came without evidence of thyroxine suppression.

    In plain wordsIn children with short stature, the TSH rise with hexarelin showed no sign of lower thyroxine.

    Peptide
    Hexarelin
    Outcome
    No significant changeThyroxine suppression
    Study

    n: not reported in source

    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · intranasal · 7 daysAs given in this study (human).

    Source sentences

    Summary
    There was also a significant, within normal limits, rise of thyroid stimulating hormone (TSH) without evidence of thyroxine suppression.
    1 context sentence
    Summary · context
    Twice or three times daily intranasal administration of the hexapeptide hexarelin for 7 days to children with short stature and normal growth hormone (GH) secretion evoked a significant rise in serum levels of insulin-like growth factor-1 (IGF-1) and alkaline phosphatase.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.